SLE (n = 66) | AAV (n = 22) | |
---|---|---|
Clinical features | ||
Females (n, (%)) | 60 (90.9) | 12 (54.5) |
Age (median (IQR)) | 36.3 (29.8–50.3) | 62.0 (44.0–70.5) |
Disease duration (median (IQR)) | 7.9 (2.6–14.3) | 1.5 (0–6.5) |
Disease activity | ||
SLEDAI-2Ka (n = 65) (median (IQR)) | 12.0 (7.0–16.0) | – |
BVAS (n = 17) (median (IQR)) | – | 15.0 (10.5–22.5) |
Rituximab treatment regimens | ||
375 mg/m2 × 4 weekly infusions (n, %) | 38 (57.6) | 5 (22.7) |
1 g 2 weeks apart (n, %) | 24 (36.4) | 13 (59.1) |
500 mg 2 weeks apart (n, %) | 4 (6.1) | 3 (13.6) |
Concomitant treatments | ||
IV cyclophosphamide (n, %) | 36 (54.5) | 10 (45.4) |
IV 6-methylprednisolone (n, %) | 37 (56.1) | 4 (18.2) |